Interleukin-15 correlates with cytotoxic immune networks in cervical tuberculous lymphadenitis - Scorecard - MDSpire

Interleukin-15 correlates with cytotoxic immune networks in cervical tuberculous lymphadenitis

  • By

  • Soumaya Bchiri

  • Khadija Bahrini

  • Rosane M. B. Teles

  • Ameni Ben Alaya

  • Houssem Eddine Kamel

  • Julie West

  • Kimia Rategh

  • Asma Bouzekri

  • Eya Bousalem

  • Rim Ouni

  • Meriem Fassatoui

  • Helmi Mardassi

  • Neira Dekhil

  • Issam Ben Belghith

  • Rym Lahiani

  • Emna Romdhane

  • Meriem Ben-Ali

  • Soumaya Rammeh

  • Asma Ferjani

  • Mamia Ben-Saleh

  • Mohamed-Ridha Barbouche

  • Robert L. Modlin

  • Chaouki Benabdessalem

  • June 3, 2026

  • 0 min

Share

Clinical Scorecard: Association of Interleukin-15 with Cytotoxic Immune Networks in Cervical Tuberculous Lymphadenitis

At a Glance

CategoryDetail
ConditionCervical Tuberculous Lymphadenitis (CTL)
Key MechanismsCytotoxic immune responses coordinated by IL-15 and associated cytokine networks.
Target PopulationPatients with cervical tuberculous lymphadenitis and non-tuberculous cervical lymphadenopathy.
Care SettingClinical settings involving diagnosis and management of lymphadenopathy.

Key Highlights

  • IL-15 identified as a central organizer of cytotoxic immune pathways in CTL.
  • Elevated IL-15 levels correlated with cytotoxic effector genes.
  • Higher circulating IL-15 concentrations in CTL compared to CNTL.
  • IL-15 and IL-15Rα expressed in macrophages within granulomatous regions.
  • GeneXpert assay provides rapid bacteriologic confirmation of CTL.

Guideline-Based Recommendations

Diagnosis

  • Utilize GeneXpert MTB/RIF assay for rapid bacteriologic confirmation.
  • Differentiate CTL from CNTL due to differing management strategies.

Management

  • Early diagnosis and appropriate treatment are critical for favorable prognosis.

Monitoring & Follow-up

  • Monitor IL-15 levels as a potential biomarker for disease progression.

Risks

  • Delays in diagnosis can adversely affect outcomes.

Patient & Prescribing Data

Patients with cervical tuberculous lymphadenitis.

Management remains challenging due to nonspecific clinical presentation.

Clinical Best Practices

  • Employ targeted immune profiling to improve diagnostic accuracy.
  • Incorporate cytotoxic mediators in diagnostic strategies.

Related Resources & Content

Original Source(s)

Interleukin-15 correlates with cytotoxic immune networks in cervical tuberculous lymphadenitis

  • by Soumaya Bchiri, Khadija Bahrini, Rosane M. B. Teles, Ameni Ben Alaya, Houssem Eddine Kamel, Julie West, Kimia Rategh, Asma Bouzekri, Eya Bousalem, Rim Ouni, Meriem Fassatoui, Helmi Mardassi, Neira Dekhil, Issam Ben Belghith, Rym Lahiani, Emna Romdhane, Meriem Ben-Ali, Soumaya Rammeh, Asma Ferjani, Mamia Ben-Saleh, Mohamed-Ridha Barbouche, Robert L. Modlin, Chaouki Benabdessalem

  • June 3, 2026

Related Content

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

Short-term risk stratification using parallel admission and reassessment features in PICU patients with infection

Efficacy and safety of ozone autohemotherapy for zoster-associated pain: a meta-analysis and trial sequential analysis